A genome-wide association study (GWAS) has identified several susceptibility loci for cervical cancer, but they explain only a small fraction of cervical cancer heritability. Other variants with weaker effect may be missed due to the stringent significance threshold. To identify important pathways in cervical carcinogenesis, we performed a two-stage pathway analysis in two independent GWASs in the Swedish population, using the single-nucleotide polymorphism (SNP) ratio test. The 565 predefined pathways from Kyoto Encyclopedia of Genes and Genomes and BioCarta databases were systematically evaluated in the discovery stage (1034 cases and 3948 controls with 632 668 SNPs) and the suggestive pathways were further validated in the replication stage (616 cases and 506 controls with 341 358 SNPs). We found 12 pathways that were significant in both stages, and these were further validated using set-based analysis. For 10 of these pathways, the effect was mainly due to genetic variation within the major histocompatibility complex (MHC) region. In addition, we identified a set of novel candidate genes outside the MHC region in the pathways denoted 'Staphylococcus aureus infection' and 'herpes simplex infection' that influenced susceptibility to cervical cancer (empirical P 5 4.99 3 10 25 and 4.99 3 10 25 in the discovery study; empirical P 5 8.98 3 10 25 and 0.009 in the replication study, respectively). Staphylococcus aureus infection may evoke an inflammatory response that inadvertently enhances malignant progression caused by HPV infection, and Herpes simplex virus-2 infection may act in conjunction with HPV infection to increase the risk of cervical carcinoma development. These findings provide new insights into the etiology of cervical cancer.
INTRODUCTION
Worldwide, cervical cancer is the third most common cancer and the second most frequent cause of cancer deaths among women (1) . Infection with oncogenic types of human papillomavirus (HPV) is a necessary, but not sufficient cause of cervical cancer and its precursor lesions, cervical intraepithelial neoplasia (CIN) where CIN III is considered the same as carcinoma in situ (CIS) or Stage 0 cervical cancer (2) . Host genetic factors play an important role for both the persistence of infection and progression to cancer (3) . We have recently performed the first genomewide association study (GWAS) of cervical cancer in a Swedish population and identified three independent susceptibility loci within the major histocompatibility complex (MHC) region at 6p21.3, in addition to the known associations with classic human leukocyte antigen (HLA) alleles/haplotypes including HLA-B * 0702, DRB1 * 1501-DQB1 * 0602 and DRB1 * 1301-DQA1 * 0103-DQB1 * 0603 (4). However, these loci together only explain 3.4% of phenotype variance of cervical cancer.
Certain limitations should be noted in the single-singlenucleotide polymorphism (SNP) analysis applied in the GWAS. First, causal variants with moderate effects are likely to be missed given the stringent multiple testing correction (5) . Secondly, the clinical manifestations of complex diseases usually arise from the interplay of multiple genetic and environmental risk factors. Identifying a small number of significant genes in GWAS may therefore be insufficient to delineate the pathogenesis of complex diseases (6) . It is increasingly recognized that the * To whom correspondence should be addressed at: Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, 751 08 Uppsala Sweden. Tel: +46 737174449; Fax: +46 184714931; Email: dan.chen@igp.uu.se; simpledandan@gmail.com pathway-based analysis, which jointly considers multiple variants in interacting or functionally related genes, may complement single-SNP analysis for interpreting GWA data of complex diseases and is likely to yield new insights into disease etiology (7) (8) (9) . Pathway analysis groups genes that are biologically related and tests whether these gene groups are associated with the outcome. Although the effects of variation at many genes may be too small to detect in single-SNP analysis, they are likely to be detected from the joint effect of many weaker signals at genes with a shared biological function. Pathway analyses have been applied to the GWASs of several complex diseases, and resulted in the identification of some novel disease-susceptibility pathways (7) (8) (9) (10) (11) (12) (13) .
To gain a better understanding of the genetic mechanisms involved in the development of cervical cancer and to identify key pathways in cervical carcinogenesis, we performed a twostage pathway analysis in two independent GWASs of cervical cancer in the Swedish population using the SNP ratio test (SRT) (14) . These two GWASs have been reported previously (4, 13) . The SRT uses both significant and non-significant SNPs within a pathway to construct a ratio and compares this ratio with a distribution of ratios based on GWAS results using randomized phenotypes. In Stage 1, 565 predefined pathways from Kyoto Encyclopedia of Genes and Genomes (KEGG) and BioCarta databases were screened in the discovery GWAS including 1034 cervical cancer patients and 3948 cancer-free control subjects with 632 668 SNPs. In Stage 2, the pathways with adjusted empirical P-values of ≤0.05 after correcting for multiple testing were validated in the replication GWAS including 616 cervical cancer patients and 506 cancer-free control subjects with 341 358 SNPs. The pathways associated with cervical cancer that were identified by the SRT were further validated by the set-based analysis in PLINK (15) .
RESULTS

Genetic information and prior biological information used in pathway analysis
Of the total 632 668 genotyped SNPs that passed quality control (QC) steps in the discovery GWAS, 91 703 SNPs were mapped to 5489 genes within the 268 KEGG pathways and 70 846 SNPs were mapped to 1042 genes within the 297 BioCarta pathways. The association tests for the original dataset resulted in 3736 nominally significant SNPs with P ≤ 0.005 and 32 148 nominally significant SNPs with P ≤ 0.05 after adjusting for the genomic inflation factor of 1.03.
Results of pathway analysis using SRT method
The P snp -value used here refers to the threshold denoting whether the original single SNP is statistically significant. For the analysis in this study, to identify significant pathways in different disease models, P snp was set to 0.005 and 0.05, respectively. Choosing a stringent threshold (P snp ≤ 0.005) to define 'associated' SNPs, tests a hypothesis that only highly associated SNPs are enriched in a pathway. Alternatively, if a pathway becomes significant using a less stringent cutoff (P snp ≤ 0.05), it reflects a role for more variants with smaller effect. If a pathway is significant under both thresholds, it suggests that this pathway may be enriched for variants of small and large effect (14) .
As summarized in Table 1 , under the SNP significance threshold of P snp ≤ 0.005, a total of 32 pathways were statistically significant in the discovery GWAS after adjustment for multiple testing (adjusted empirical P ≤ 0.05). Among them, 11 pathways were successfully replicated in the replication GWAS, including hsa04145 (phagosome, empirical P ¼ 0.022), hsa04612 (antigen processing and presentation, empirical P ¼ 9.98 × 10
24
), hsa04672 (intestinal immune network for IgA production, empirical P ¼ 0.020), hsa04940 (type 1 diabetes mellitus, empirical P ¼ 9.98 × 10
), hsa05150 (Staphylococcus aureus infection, empirical P ¼ 8.98 × 10
), hsa05310 (asthma, empirical P ¼ 8.62 × 10
), hsa05320 (autoimmune thyroid disease, empirical P ¼ 0.025), hsa05330 (allograft rejection, empirical P ¼ 0.015), hsa05332 (graft-versus-host disease, empirical P ¼ 0.016), mhcPathway (antigen processing and presentation, empirical P ¼ 0.036) and eosinophilsPathway (the role of eosinophils in the chemokine network of allergy, empirical P ¼ 0.046). Notably, both the pathways representing the biological process 'antigen processing and presentation' from the KEGG and BioCarta databases, i.e. hsa04612 and mhcPathway showed statistically significant associations with risk of cervical cancer, although the gene contents of the two pathways are not exactly the same, indicating the important role of antigen processing and presentation in cervical cancer pathogenesis.
Using a less stringent SNP significance threshold (P snp ≤ 0.05), hsa05168 (herpes simplex infection) was found to be significant in both the discovery and replication studies (empirical P ¼ 4.99 × 10 25 and 0.009, respectively), suggesting that more variants of smaller effect are enriched in this pathway. It is worth noting that pathways of hsa04612, hsa04940, hsa05150, hsa04145, mhcPathway and hsa05310 were consistently significant in both stages under the SNP significance threshold of both P snp ≤ 0.005 and 0.05 ( Table 2 ), suggesting that these pathways are enriched for variants of small and large effect. Alternatively, a small number of variants of larger effect are enriched in the pathways of hsa04672, hsa05320, hsa05330, hsa05332 and eosinophilsPathway, which were only significant under the SNP significance threshold of P snp ≤ 0.005. In total, 12 significant pathways were identified under the SNP significance threshold of P snp ≤ 0.005 and 0.05. All the 12 pathways are shown in Supplementary Material, Figs S1-S12. The representative SNPs associated with risk of cervical cancer at P ≤ 0.005 for each gene in the discovery and replication studies are shown in Supplementary Material, Tables S1 and S2, respectively.
The discovery and replication GWASs were genotyped using two different SNP genotyping platforms, i.e. Illumina Omni Express for the discovery GWAS and Affymetrix Genome-wide Human SNP arrays 5.0 for the replication GWAS, respectively, and there are only 88 133 overlapping SNPs between these two studies. SNPs that were genotyped only in one study but not in the other were imputed using the 1000 Genomes Project data as a scaffold (see Materials and Methods). As the SRT can only use the raw genotype data instead of SNP P-values, the two GWASs containing imputed SNP data that passed QC were merged to perform a joint analysis of the 12 identified pathways instead of meta-analysis. In the combined dataset of the discovery and replication GWASs, most of the 12 identified pathways were Table S3 ). However, hsa04940 (type 1 diabetes mellitus) and mhcPathway (antigen processing and presentation)
were statistically significant under the SNP significance threshold of P snp ≤ 0.005 (empirical P ¼ 0.045 and 0.025, respectively).
Results of pathway analysis using set-based analysis
The 12 pathways associated with risk of cervical cancer that were identified by the SRT were further validated using the set-based analysis in PLINK in both the discovery and replication GWASs (15) . As summarized in Table 3 , comparable results were Adjusted empirical P-values were calculated using the Benjamini and Hochberg (55) step-up FDR controlling procedure (independent and positive regression-dependent test statistics) for multiple testing correction. The bold values correspond to the pathways that were statistically significant in both the discovery and replication GWASs.
obtained using the set-based analysis, except that the pathways of hsa04940 (type 1 diabetes mellitus) and hsa05150 (S. aureus infection) were borderline significant in the replication study under the SNP significance threshold of P snp ≤ 0.005 (P ¼ 0.058 and 0.059, respectively), suggesting that SRT has better sensitivity in identifying pathways associated with cervical cancer where a small number of variants of larger effect are enriched. Nevertheless, these two pathways were statistically significant in both the discovery and replication studies under the SNP significance threshold of P snp ≤ 0.05, indicating that more variants with smaller effect in these pathways are involved in the pathogenesis of cervical cancer.
Sensitivity analysis by removing the extended MHC region
All the 12 significant pathways identified in the present study are related to the immune system, which harbor HLA genes along with a number of other genes located within and outside the extended MHC region on chromosome 6 (Supplementary Material, Tables S1 and S2). Ten genes with significant signals contribute to more than two pathways, all of which are from the extended MHC region, including HLA-DRA, HLA-DRB1, HLA-DQA2, HLA-DQB1, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-A, HLA-B and transporter 2, ATP-binding cassette, subfamily B (TAP2) (Supplementary Material, Table S4 ). Given the complex linkage disequilibrium (LD) pattern that extends across multiple HLA and non-HLA genes in the extended MHC region, the effects of these genes are not independent. In order to evaluate the impact of the genetic variation in the extended MHC region on pathway association and to identify genetic factors outside it, SNPs in the extended MHC region (from 25 640 149 to 33 368 333 bp on chromosome 6) were removed from the pathway analysis for sensitivity analysis. This includes the extended Class I, Class I, Class III, Class II and extended Class II region from the telomeric to centromeric end of 6p21. The analysis using the SRT performed on the non-MHC data showed that the pathways hsa05150 (S. aureus infection) and hsa05168 (herpes simplex infection) remained statistically significant in both studies (empirical P ¼ 6.48 × 10 24 and 0.036 in the discovery study; empirical P ¼ 0.013 and 0.032 in the replication study, respectively) under the SNP significance threshold of P snp ≤ 0.005 and 0.05, respectively (Table 4) . For the pathway 'S. aureus infection', the association signals are derived from a small number of variants with large effect in four genes in the discovery study; complement factor I (CFI), complement component 1s subcomponent (C1S), formyl peptide receptor 3 (FPR3) and integrin beta 2 (ITGB2), as well as two genes in the replication study; mannan-binding lectin serine protease 1 (MASP1) and selectin P ligand (SELPLG) ( Table 5 ). On the other hand, the association with the pathway 'herpes simplex infection' is attributable to more variants of small effect in 31 genes in the discovery study and 15 genes in the replication study, with serine/arginine-rich splicing factor 6 (SRSF6), cullin 1 (CUL1), eukaryotic translation initiation factor 2-alpha kinase 2 (EIF2AK2), eukaryotic translation initiation factor 2-alpha kinase 4 (EIF2AK4), mitogen-activated protein kinase 10 (MAPK10), POU class 2 homeobox 3 (POU2F3), 2 ′ -5 ′ -oligoadenylate synthetase 3 (OAS3) and TATA box-binding protein-associated factor 3 (TAF3) showing the strongest effects (Table 6) . No statistically significant associations were observed Derived from unconditional logistic regression assuming a log-additive model adjusted by PCs significantly associated with case-control status (P , 0.05) and further corrected for inflation factor when necessary. b Empirical P-value determined by the SRT based on 20 048 alternative phenotype simulations with cutoff of P snp ≤ 0.05 for denoting significant SNPs.
c Adjusted empirical P-values were calculated using the Benjamini and Hochberg (55) step-up FDR controlling procedure (independent and positive regression-dependent test statistics) for multiple testing correction. The bold values correspond to the pathways that were statistically significant in both the discovery and replication GWASs.
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Human Molecular Genetics, 2014, Vol. 23, No. 22 Table 3 . Validation of significant pathways identified by the SRT using set-based analysis Number of significant SNPs with below P, which is the threshold for denoting significant SNPs. Association results were derived from unconditional logistic regression assuming a log-additive model adjusted by PCs significantly associated with case-control status (P , 0.05). b Number of independently significant SNPs based on an r 2 threshold of 0.6. c Empirical P-value determined by the set-based test in PLINK based on 20 048 alternative phenotype simulations with N independent SNPs at an r 2 threshold of 0.6 and cutoff of P snp for denoting significant SNPs. d Adjusted empirical P-values were calculated using the Benjamini and Hochberg (55) step-up FDR controlling procedure (independent and positive regression-dependent test statistics) for multiple testing correction. The bold values correspond to the pathways that were statistically significant in both the discovery and replication GWASs.
for the other 10 pathways after removing SNPs in the extended MHC region ( Table 4 ), suggesting that the associations with these pathways are exclusively driven by genetic variation in genes within the extended MHC region.
There are 11 and 9 overlapping genes in the discovery and replication studies, respectively, between S. aureus and herpes simplex infection pathways, all of which are HLA genes (HLA-DRB1, HLA-DRA, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DPA1, HLA-DPB1, HLA-DMA, HLA-DMB, HLA-DOA and HLA-DOB). The S. aureus infection pathway includes 27 and 14 other genes in the discovery and replication studies, respectively, whereas the herpes simplex infection pathway includes 143 and 99 other genes in the discovery and replication studies, respectively. After removing these overlapping HLA genes, both pathways were statistically significant in both the discovery and replication studies (Supplementary Material, Table S5 ), suggesting that the associations with these two pathways are not only driven by the shared HLA genes.
When testing all the pathways without HLA genes (HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-E, HLA-F and HLA-G), none of the pathways remained statistically significant after correction for multiple testing in the discovery study. Nevertheless, the pathways of 'S. aureus infection' and 'Herpes simplex infection' showed statistically significant association with risk of cervical cancer in the replication study (P ¼ 0.012 and 0.021, respectively) (Supplementary Material, Table S6 ), suggesting that candidate genes other than HLA genes in these two pathways may be involved in the pathogenesis of cervical cancer.
DISCUSSION
GWASs using single-SNP analysis have been very successful in identifying common genetic variation underlying complex diseases in recent years. However, this approach may miss the causal genes with moderate genetic effects due to the stringent significance threshold of GWASs. Compared with single-SNP analysis, pathway analysis combines the association evidence of multiple functionally related genes within a pathway, and potentially has greater power to reveal the biological mechanism(s) underlying complex diseases (5) . Other benefits of this approach are the substantial reduction of the multiple testing burden once genes are grouped into pathways for association testing and the incorporation of biological knowledge into the analysis, which is not accounted for in single-SNP analysis. The SRT has several major advantages compared with other methods. First, the magnitude of any one-association statistic is not key, but rather the number of significant SNPs above what would be expected by chance is key, making the SRT more robust to false positives at an SNP level. Second, the SRT uses phenotype permutation to correct naturally for biases introduced by LD and gene size (14, 16) . It keeps all the information constant and only permutes the case-control status among individuals. The same individuals are used, maintaining the same LD structure. This minimizes false-positive associations arising from LD because, even if LD was leading to an excess of significance for a pathway, this LD block would be identical across all datasets using randomized phenotypes. The same is true for gene size, since a larger gene has more potential SNP sites and therefore more potential false positives, but this bias will be the same 
for the original and the simulated datasets. Last but not least, covariates such as population stratification in GWAS can be adjusted in the SRT. The SRT has been successfully applied to the GWAS of several complex diseases (11 -13) .
In the present study, we used the SRT and identified 12 pathways that are associated with the development of cervical cancer in the Swedish population. These findings were further replicated using another method and another independent study. Among them, 'antigen processing and presentation', 'type 1 diabetes mellitus', 'S. aureus infection', 'phagosome', mhcPathway and 'asthma' are enriched for variants of small and large effect. In addition, a small number of variants of relatively large effect are enriched in the pathways of 'intestinal immune network for IgA production', 'autoimmune thyroid disease', 'allograft rejection', 'graft-versus-host disease' and eosinophilsPathway, while more variants of small effect are enriched in the pathway 'herpes simplex infection'. These findings suggest that a number of different genetic models underlie cervical cancer, as is the case for many complex diseases. All the identified pathways are related to the immune response and 10 of them are mainly driven by genetic variation in genes within the extended MHC region, supporting the importance of the MHC region in cervical cancer pathogenesis, in particular, HLA molecules that present antigens to the immune system. On the other hand, in addition to genes within the MHC region, the associations with the pathways 'S. aureus infection' and 'herpes simplex infection' are also attributable to genes outside the extended MHC region, the majority of which have not been studied in the context of cervical cancer.
In a previous pathway-based analysis based on 216 KEGG pathways, the pathways 'asthma' (empirical P ¼ 0.03), 'folate biosynthesis' (empirical P ¼ 0.04) and 'graft-versus-host disease' (empirical P ¼ 0.05) were found to be significantly associated with risk of cervical cancer (13) . The associations with 'asthma' and 'graft-versus-host disease' but not 'folate biosynthesis' were also observed in our study. Given the lack of adjustment for multiple testing and replication in an independent cohort in the previous study (13) , the role of 'folate biosynthesis' in the development of cervical cancer warrants further evaluation. A recent GWAS of cervical cancer in the Han Chinese population has identified three susceptibility loci. The first is between HLA-DPB1 and HLA-DPB2; the second is in exocyst complex component 1 gene (EXOC1) at 4q12; and the third is 9.5 kb downstream of gasdermin B (GSDMB) (17) at 17q12. In our study, we found that variation in HLA-DPB1 contributed to 10 pathways that were significantly associated with cervical cancer (Supplementary Material, Table S4 ), suggesting an important role of HLA-DPB1 in the pathogenesis of cervical cancer. However, neither EXOC1 nor GSDMB is present in the pathways from KEGG and BioCarta databases analyzed in our study. Further studies are warranted to validate the findings for EXOC1 and GSDMB in non-Asian populations.
In addition to the variants in the extended MHC region, the association with pathway 'S. aureus infection' seems to be mainly determined by a small number of variants with relatively large effect in the genes C1S, CFI, FPR3, ITGB2, MASP1 and SELPLG. While no studies have investigated the association between S. aureus infection and cervical cancer, a recent finding may suggest a role of S. aureus infection in epithelial carcinoma caused by HPV infection. In a transgenic model of epithelial carcinogenesis induced by HPV 16 oncogenes, infiltrating CD4
+ T cells were detected in both premalignant Association results were derived from unconditional logistic regression for minor allele assuming a log-additive model corrected for the observed inflation factor (l ¼ 1.03). None of the PCs generated from PCA was significantly associated with case -control status (all P . 0.05) hence not included in the final model. Association results were derived from unconditional logistic regression for minor allele assuming a log-additive model with adjustment of three PCs generated from PCA which were significantly associated with case -control status (P , 0.05) with l ¼ 1.00 Association results were derived from unconditional logistic regression for minor allele assuming a log-additive model corrected for the observed inflation factor (l ¼ 1.03). None of the PCs generated from PCA was significantly associated with case -control status (all P . 0.05) hence not included in the final model. Association results were derived from unconditional logistic regression for minor allele assuming a log-additive model with adjustment of three PCs generated from PCA which were significantly associated with case -control status (P , 0.05) with l ¼ 1.00.
and malignant lesions, which functionally promoted epithelial carcinogenesis. Remarkably, CD4 + T-cell reactivity was predominantly directed toward antigens expressed by the Staphylococcal bacteria infecting the dysplastic skin lesions, not the HPV16 oncogenes, suggesting that S. aureus infection may evoke an inflammatory response that inadvertently enhances malignant progression (18) . CFI, C1S and MASP1 encode serine proteases of the complement system which is involved in host defense against infectious agents, more specifically in the removal of apoptotic cells and immune complexes, and in the modulation of the adaptive immune system (19) . As shown in Supplementary Material, Fig. S11 , the complement system can be activated via three major routes: the classical, alternative and lectin pathways. CFI is a crucial inhibitor controlling all complement pathways and complete CFI deficiency is strongly associated with severe infections (20) . C1S is a subunit of the first component of the complement system (C1), which can recognize different types of activators and initiate the activation of the classical pathway (21) . MASP1 functions as a component of the lectin pathway of complement activation which may play a role as an amplifier of complement activation by cleaving complement C2 or by activating another complement serine protease, MASP-2 (22, 23) . A splice variant of MASP1 which lacks the serine protease domain, functions as an inhibitor of the complement pathway (24) . FPR3, also known as FPRL2, is expressed on dendritic cells (DCs) throughout their maturation and the interaction of FPR3 and its endogenous ligand (s) may be involved in regulating DC trafficking during antigen uptake and processing in the periphery as well as the T-cell-stimulating phase of the immune response (25) . ITGB2 encodes the beta-2 integrin subunit of the leukocyte cell adhesion molecule that participates in cell adhesion and cell-surface mediated signaling (26) . Defects in this gene cause leukocyte adhesion deficiency type I (LAD1), which is characterized by recurrent bacterial infections (27) , and genetic variation in ITGB2 has been significantly associated with the development of papillary thyroid cancer (28) . SELPLG encodes a glycoprotein that functions as a high-affinity counter-receptor for the cell adhesion molecules P-, E-and L-selectin expressed on myeloid cells and stimulated T lymphocytes. As such, this protein plays a critical role in leukocyte trafficking during inflammation by tethering of leukocytes to activated platelets or endothelia expressing selectins (29) . Aberrant expression of this gene and polymorphisms in this gene are associated with defects in the innate and adaptive immune response (30, 31) . As cervical cancer is caused by persistent HPV infection, these genes that are involved in the immune response against infections may also play a role in the pathogenesis of cervical cancer.
The association of cervical cancer with pathway 'herpes simplex infection' is driven by a number of variants with small effect in 31 genes in the discovery study and 15 genes in the replication study after removing variants in the extended MHC region, with SRSF6, CUL1, EIF2AK2, EIF2AK4, MAPK10, POU2F3, OAS3 and TAF3 showing the strongest effects. Herpes simplex virus (HSV) includes two types: HSV-1 and HSV-2. HSV-1 causes primarily oral infections, whereas HSV-2, like HPV, can infect cervical squamous epithelial tissue in the squamocolumnar junction, where invasive cervical cancer arises (32) . Synergisms between HPV and HSV-2 in induction of cervical cancer have been shown in epidemiological studies and confirmed by laboratory experiments (33) (34) (35) (36) (37) (38) . These studies indicate that simultaneous infection with HPV and HSV-2 increases the risk of cervical cancer when compared with infection with either HPV-16 or HPV-18 alone. It has been assumed that HSV-2 initiates the process and infection with HPV occurs later (39) . Indeed, herpetic lesions can facilitate the access of HPV to basal cells and inflammatory responses induced by HSV-2 infection may decrease T helper cells' capacity to produce efficient immune response (40) . Alternatively, HSV-2 infection can increase the risk of cervical carcinogenesis by inducing the production of nitric oxide that may result in cellular DNA damage in HPV-infected cells (41) . Therefore, it is biologically plausible that genes involved in the HSV-2 infection pathway may also play a role in the development of cervical cancer. The splicing factor SRSF6 is involved in the mRNA alternative splicing and is found to be an oncoprotein that regulates the proliferation and survival of lung and colon cancer cells (42) . CUL1 is member of cullin protein family required for ubiquitin-dependent protein degradation and CUL1-containing ubiquitin ligase plays a role in the ubiquitination and proteolysis of the E7 HPV oncoprotein (43) . EIF2AK2 and EIF2AK4 are two members of the serine -threonine kinases family that phosphorylate the a-subunit of eukaryotic initiation factor 2 (eIF2a), in response to stress signals. eIF2a phosphorylation by EIF2AK2 in response to viral infection results in arrest of viral mRNA translation and apoptosis, an efficient way to inhibit virus replication (44) . Pronounced EIF2AK4 activation was observed in human tumors while compromising EIF2AK4 signaling severely hampered tumor growth in vivo, suggesting the EIF2AK4 pathway is critical for maintaining metabolic homeostasis in tumor cells (45) . MAPK10 is a member of the MAP kinase family, which has proapoptotic functions and can function as a tumor-suppressor gene (46) . POU2F3 is a keratinocyte-specific POU transcription factor and is also a candidate tumorsuppressor protein, and aberrant promoter methylation of this gene may play a role in cervical cancer (47) . OAS3 encodes an enzyme which plays a significant role in the inhibition of cellular protein synthesis and viral infection resistance (48) . TAF3 is a subunit of the RNA polymerase II transcription factor which contributes to promoter recognition and selectivity, and acts as anti-apoptotic factor (49) . These genes may thus be involved in the persistence of HPV infection or cervical cancer development.
As shown in the Materials and Methods, genetic variants that exist on either Illumina HumanOmniExpress BeadChip or Affymetrix Genome-wide Human SNP arrays 5.0 were imputed in the combined dataset and QC was applied to exclude genetic variants that were poorly imputed or showed statistically significant difference in minor allele frequency (MAF) between the discovery and replication GWASs. In the combined dataset, the eosinophilsPathway was borderline significant under the SNP significance threshold of P snp ≤ 0.005, and hsa04940 (type 1 diabetes mellitus) and mhcPathway (antigen processing and presentation) were not statistically significant under the SNP significance threshold of P snp ≤ 0.05 (Supplementary Material, Table S3 ). However, these pathways were found to be statistically significant in both the discovery and replication studies using SRT or set-based analysis. It is worth noting that the SNP density of these three pathways in the combined dataset is much lower than that of the discovery GWAS (16 SNPs SNPs compared with 40 SNPs, respectively), which could reduce the study power. This is due to the fact that some SNPs in these pathways that were genotyped in the discovery GWAS were poorly imputed in the replication GWAS, especially those in the MHC region given its complex LD structure, and therefore were removed from the combined dataset. It is also important to validate the imputation results for the SNPs in these pathways before drawing any firm conclusion.
The results of pathway-based analyses can be validated in independent materials using either additional GWAS data or targeted genetic analyses of the genes in pathways indicated in the original study. The former has the advantage that a genomewide selection of SNP is available for validation, but may be difficult to perform due to lack of such data. The latter requires genotyping of selected SNPs in genes in pathways of interest using custom SNP arrays. This also requires access to additional cohorts, but if such samples are available custom genotyping may be less costly and therefore could involve a larger set of samples. Genotyping of variation in key genes in the pathways indicated can also be expanded to include variants in addition to those present on the original SNP array. In the present investigation, we do not have access to further clinical materials that could be genotyped. There has only been one other cervical cancer GWAS published, in a Chinese material. A future step might therefore be to validate the top pathways in the Chinese GWAS data. However, there were substantial differences in the primary results reported by the Swedish and Chinese GWASs, indicating that there might be differences in the etiology of cervical cancer, and the pathways involved between these populations. A more optimal approach would be to interrogate further cohorts of European descent.
This study has several strengths. First, correction for multiple testing was performed in order to control the type I error. Second, we performed a two-stage pathway analysis in two independent cohorts from the Swedish population, which may reduce the false-positive findings and improve the credibility of the results. Third, the 12 significant pathways identified by SRT were also validated using another well-established method, setbased analysis, which can also correct for biases introduced by gene size and LD. Nevertheless, several limitations in the present study need to be acknowledged. First, incomplete annotation of the human genome may reduce the study power for the pathway analysis, since many genes are uncharacterized and SNPs in these genes or intergenic SNPs physically far away from genes were not included. Hence, the pathway-based analysis can complement but not replace the single-SNP approach. Second, as with other methods, the SRT is less equipped to identify significant pathways when there is a paucity of SNPs arising within pathways ( PG SNP); if there are no significant PG SNP, the ratio is always 0 for the original data. Thus, all simulations will at least equal this ratio, resulting in an empirical P-value of 1. These limits reflect both the limits of pathway annotation and the power of the GWAS dataset used. Thus, adequate SNP coverage of a pathway is essential for that pathway to be effectively tested. Finally, the amount and diversity of SNPs measured per pathway is highly variable between the genotyping platforms used for the discovery and replication GWAS datasets. Despite this fact, 12 pathways were replicated with a different technical platform and method, providing credible evidence that these pathways influence susceptibility to cervical cancer. It is worth noting that the SNP density of the replication GWAS is much lower than that of the discovery GWAS, which reduces the study power for replicating significant pathways. Therefore, pathways identified in the discovery phase but failed in the replication study warrant further validation in another independent study with higher SNP coverage.
In summary, we have conducted a two-stage pathway analysis in GWASs of cervical cancer in the Swedish population. The successful identification and replication of 12 cervical cancer susceptibility pathways demonstrates the power and applicability of the pathway-based approach in the analysis of GWA data. The associations of 10 pathways are mainly determined by genes in the MHC region, supporting the importance of the MHC region in cervical cancer pathogenesis. In addition, we have identified a number of novel candidate genes outside the MHC region in the pathways denoted 'S. aureus infection' and 'herpes simplex infection' that influence the susceptibility to cervical cancer, providing new insights into etiology of cervical cancer. Our results demonstrate that a pathway-based analysis that incorporates information from markers with moderate significance levels, can greatly facilitate the interpretation of GWA data and leads to the identification of novel diseasesusceptibility genes and mechanisms. The identified causal pathways may help formulate new hypotheses or substantiate existing hypotheses regarding disease etiology, and genes that rank high in these pathways can serve as candidates for genetic and functional follow-up studies.
MATERIALS AND METHODS
Study population
Discovery stage
Subjects included in the discovery stage were from a GWAS of cervical cancer generated on the Illumina Omni Express BeadChip (Illumina, San Diego, CA, USA) (731 422 SNPs) in a Swedish population. The details of population and QC have been described elsewhere (4) . Briefly, after stringent QC, data from 1034 cervical cancer patients (971 CIS and 63 invasive carcinoma) and 3948 control subjects were available for 632 668 SNPs with an overall call rate of 99.92%. The potential for population stratification was investigated by principal components analysis (PCA) undertaken with the EIGENSTRAT package (50) . None of the principal components (PCs) derived from PCA was statistically significantly associated with case-control status (all P . 0.05).
Replication stage
The replication GWA dataset was generated on the Affymetrix Genome-wide Human SNP arrays 5.0 with 440 794 SNP markers, which represents mostly different markers compared with the Illumina arrays used in the discovery GWAS. In brief, 617 unrelated cervical cancer patients (598 CIS and 19 invasive carcinoma) were selected from families with at least two affected women from Sweden and genotype data of 519 controls in Sweden was downloaded from the Nordic Control Allele Frequency and Genotype Database created by the Nordic Center of Excellence in Disease Genetics program (51) . Systematic QC common to both datasets was conducted separately for the Genotype data from the two datasets were merged and further QC was applied. The exclusion criteria for SNPs were: (i) genotyping call rate ,97%, (ii) heterozygous haploid genotypes, (iii) multi-mapping sites, (iv) genotype frequency that deviated from Hardy -Weinberg equilibrium (HWE) among control subjects (P , 1 × 10 27 ) and (v) a statistically significant difference in missing rate between case subjects and control subjects (P , 1 × 10
27
). Samples were excluded if heterozygosity rates for autosomal chromosomes were .6 SDs from the mean. We also conducted further exclusions for those with abnormal heterozygosity rate on the X chromosome. Unexpected duplicates and the first-and second-degree relatives were removed based on identity-by-state (IBS) estimates calculated in PLINK (15) . To maximize the ethnic homogeneity of the case and control series and to capture other potential underlying structures in the data, we performed a PCA undertaken with the EIGENSTRAT (50) package using a subseries of 19 959 SNPs that are evenly distributed across the genome in low LD (pairwise r 2 , 0.03). This resulted in further exclusion of four outliers. After systematic QC steps, data from 616 case subjects (597 CIS and 19 invasive carcinoma) and 506 control subjects were available for 341 358 SNPs with an overall call rate of 99.79% (Supplementary Material, Table S7 ). Three PCs derived from PCA were statistically significantly associated with case -control status (P , 0.05).
Informed consent was obtained from all subjects, and each study was approved by the regional ethical review board.
Imputation and merging two GWASs
The replication GWA dataset was changed to hg19 from hg18 using the USCS LiftOver tool (http://genome.sph.umich.edu/ wiki/LiftOver). Both the discovery and replication GWAS datasets were separately phased using the shapeit-tool (52). They were then separately split into chunks of 5 Mb containing at least 200 genotyped SNPs. No chunks spanned the centromeres. Genetic variants across each chunk not genotyped on the Ilumina HumanOmniExpress BeadChip or Affymetrix Genome-wide Human SNP arrays 5.0 were imputed for the discovery and replication GWASs, respectively, using the program IMPUTE2 (53) with phased haplotypes in subjects from the December 2013 release of the 1000 Genomes Project data (https://mathgen.stats. ox.ac.uk/impute/impute_v2.html#reference) (54) as a scaffold. Imputed variants with info-score , 0.3 in either dataset were removed. The two datasets were then merged and markers with ,0.9 in posterior genotypic probability in .5% of the samples or monomorphic were removed. Finally, genotypes were called from posterior probabilities using 0.9 as threshold using gtool (http://www.well.ox.ac.uk/~cfreeman/software/gwas/gtool.html). Genetic variants that exist on either Ilumina HumanOmniExpress BeadChip or Affymetrix Genome-wide Human SNP arrays 5.0 were included for further analysis. Further QC was applied to the merged dataset. The exclusion criteria for genetic variants were: (i) genotype frequency that deviated from HWE among control subjects (P , 1 × 10
27
) and (ii) a statistically significant difference in MAF between the discovery and replication GWASs (P , 1 × 10
). Unexpected duplicates (11 subjects) and firstand second-degree relatives (9 subjects) were removed based on IBS estimates calculated in PLINK (15) . Utilizing a set of 15 872 SNPs genotyped in both GWASs and evenly distributed across the genome in low LD (pairwise r 2 , 0.02), a PCA using the EIGENSTRAT software (50) excluded eight additional samples detected as outliers. After stringent QC, data from 1634 cases and 4442 controls were available for 747 046 SNPs with an overall call rate of 99.32%. The potential for population stratification was investigated by PCA undertaken with the EIGENSTRAT package (50) . One PC derived from PCA was statistically significantly associated with case-control status (P , 0.05). The association results of the 747 046 SNPs included in the joint analysis are available in 'http://www.genpat.uu.se/ research/genetics_genomics/gyllensten/data/', and are derived from unconditional logistic regression assuming a log-additive genetic model adjusted by one PC statistically significantly associated with case-control status.
Pathway analysis
Pathways were collected from two resources: KEGG (http ://www.genome.jp/kegg/pathway.html) and BioCarta databases (http://www.biocarta.com/genes/index.asp) (as of July 2013). Two hundred and sixty-eight pathways from KEGG database and 297 pathways from BioCarta database were analyzed in the present study. SNP data were obtained from dbSNP (ftp:// ftp.ncbi.nih.gov/snp/organisms/human_9606/database/organism _data/b135_SNPContigLocusId_37_3.bcp). Genes annotated in this file, which includes SNPs in upstream (2 kb) and downstream (0.5 kb) regions, were merged with those in the pathways to create a file linking pathways and SNP information using the Human Genome Organization gene nomenclature.
The association between each SNP and cervical cancer risk was estimated using unconditional logistic regression assuming a log-additive genetic model in PLINK (15) . Adjustment for population stratification was performed by including PCs derived from PCA that were statistically significantly associated with case-control status (P , 0.05) as covariates in the logistic regression. In the discovery GWAS, none of the PCs was statistically significantly associated with case-control status (all P . 0.05) hence not included in the final model, while in the replication and combined GWASs, three and one PCs which were significantly associated with case -control status (P , 0.05) were included as covariates in the final model, respectively. Genomic control was subsequently applied in SRT, and all the P-values were corrected for the observed inflation when necessary (l ¼ 1.03, 1.00 and 1.11 for the discovery, replication and combined GWASs, respectively).
SNP ratio test
The SRT computes an 'SNP ratio' for each pathway, i.e. it divides the number of significant markers (P-value below a certain threshold P snp ) by the number of non-significant markers within a pathway. To estimate the significance of each pathway, we randomized the case-control status of individuals in the original GWAS data to generate 20 048 simulated GWAS datasets while preserving the overall ratio of cases to controls and then calculated an empirical P-value based on the simulated datasets. The number of significant SNPs in the simulated GWAS datasets is defined as the top n SNPs with the lowest
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